Pharmacoeconomic analysis of trastuzumab emtanzine comparing to lapatinib + capecitabine in pa-tients with HER2+ breast cancer and central nervous system metastases
Aim. To perform health-economic evaluation of trastuzumab emtansine (T-DM1) in patients with HER2+ breast cancer and CNS metastases. Materials and methods. Cost-effectiveness analysis along with sensitivity analysis and budget impact analysis were performed. Direct medical costs and indirect costs (...
Saved in:
Main Authors: | A. S. Kolbin (Author), A. A. Kurylev (Author), Yu. E. Balykina (Author), M. A. Proskurin (Author), D. R. Naskhletashvili (Author) |
---|---|
Format: | Book |
Published: |
Izdatelstvo OKI,
2018-05-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
An update of pharmacoeconomic analysis of trastuzumab emtanzine in patients with HER2+ breast cancer and central nervous system metastases
by: A. S. Kolbin, et al.
Published: (2019) -
Pharmacoeconomic analysis of denosumab in patients with breast cancer and bone metastases
by: A. S. Kolbin, et al.
Published: (2018) -
Pharmacoeconomic evaluation of ipragliflozin in combination with metformin in comparison with other regimens of therapy for type 2 diabetes mellitus
by: A. S. Kolbin, et al.
Published: (2021) -
Pharmacoeconomic analysis of vemurafenib and dabrafenib use in patients with inoperable or metastatic melanoma with BRAF V600 mutation
by: A. S. Kolbin, et al.
Published: (2018) -
Hepatic toxicity in HER-2(+) breast cancer patient under treatment with capecitabine and lapatinib
by: Elia Romero Carreño, et al.
Published: (2016)